Fig. 6
Roles of hippocampal BDNF in the improving effects of rhANP on LPS-induced cognitive dysfunction. a Treatment schedule. Mice were intraperitoneally injected with lipopolysaccharides (LPS, 5 mg/kg). Recombinant human ANP (rhANP; 1.0 mg/kg) or 0.9% saline (10 ml/kg) were intraperitoneally injected to mice at 24 h before and 10 min after LPS injection. ANA-12 (0.5 mg/kg) or 17% dimethylsulfoxide (DMSO) was administrated 30 min prior to rhANP treatment. Entries in the novel arm (b; two-way ANOVA: rhANP: F1,36 = 3.302, P = 0.0775; ANA-12: F1,36 = 9.635, P = 0.0037; interaction: F1,36 = 2.041, P = 0.1617) and duration in the novel arm (c; two-way ANOVA: rhANP: F1,36 = 18.14, P = 0.0001; ANA-12: F1,36 = 4.792, P = .0352; interaction: F1,36 = 6.668, P = 0.0140) in the Y maze test. d Latency to eat food in the buried food test (two-way ANOVA: rhANP: F1,36 = 38.53, P < 0.0001; ANA-12: F1,36 = 3.738, P = 0.0611; interaction: F1,36 = 2.262, P = 0.1413). Data are shown as mean ± SEM, n = 10/group. *P < 0.05, **P < 0.01, ***P < 0.0001; N.S. not significant